Primary objectives: To determine whether local anesthetic transperineal (LATP) prostate biopsy improves the detection of clinically significant prostate cancer (csPCa), defined as International Society of Urological Pathology (ISUP) Grade Group ≥2 disease (i. e. any Gleason pattern 4 disease), compared to transrectal ultrasound-guided (TRUS) prostate biopsy, in biopsy-naïve men undergoing biopsy based on suspicion of csPCa.
To compare i) infection rates, ii) health-related quality of life (HRQoL), iii) patient-reported procedure tolerability, iv) patient-reported biopsy-related complications (including bleeding, bruising, pain, loss of erectile function), v) number of subsequent prostate biopsy procedures required, vi) cost-effectiveness, vii) other histological parameters, and viii) burden and rate of detection of clinically insignificant PCa (ciPCa) (ISUP Grade Group 1 disease) in men undergoing these two types of prostate biopsy.
The TRANSLATE trial is a UK-wide, multi-centre, randomised clinical trial that meets the criteria for level-one evidence in diagnostic test evaluation. TRANSLATE is investigating whether LATP biopsy leads to a higher rate of detection of csPCa compared to TRUS prostate biopsy. Both biopsies are being performed with an average of 12 systematic cores in 6 sectors (depending on prostate size), plus 3-5 target cores per multi-parametric/bi-parametric magnetic resonance imaging (mp/bp-MRI) lesion. LATP biopsy is performed using an ultrasound probe-mounted needle guidance device (either the "Precision-Point" or BK UA1232 system). TRUS biopsy is performed according to each hospital's standard practice. The study is 90% powered to detect a 10% difference (LATP biopsy hypothesised at 55% detection rate for csPCa, versus 45% for TRUS biopsy). 1,042 biopsy-naïve men referred with suspected PCa need to be recruited.
This trial will provide robust prospective data to determine the diagnostic ability of LATP biopsy versus TRUS biopsy in the primary diagnostic setting.
BJU international. 2023 Jan 25 [Epub ahead of print]
R J Bryant, H Yamamoto, B Eddy, S Kommu, K Narahari, A Omer, T Leslie, Jwf Catto, D J Rosario, D Good, R Gray, Mpc Liew, J F Lopez, T Campbell, J M Reynard, S Tuck, V S Barber, N Medeghri, L Davies, M Parkes, A Hewitt, F Landeiro, J Wolstenholme, R Macpherson, C Verrill, I R Marian, R Williams, F C Hamdy, A D Lamb
Department of Urology, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK., Department of Urology, Maidstone and Tunbridge Wells NHS Trust, Maidstone Hospital, Maidstone, UK., Department of Urology, East Kent Hospitals University NHS Foundation Trust, Kent and Canterbury Hospital, Canterbury, UK., Department of Urology, Cardiff and Vale University Health Board, University Hospital of Wales, Cardiff, UK., Department of Urology, University Hospital, s Coventry and Warwickshire NHS Trust, University Hospital, Coventry, UK., Academic Urology Unit, University of Sheffield and Department of Urology, Sheffield University Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK., Department of Urology, NHS Lothian, Western General Hospital, Edinburgh, UK., Department of Urology, Buckinghamshire Healthcare NHS Trust, Wycombe Hospital, High Wycombe, UK., Department of Urology, Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, UK., Oxfordshire Prostate Cancer Support Group, Oxford, UK., Oxford Clinical Trials Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK., Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK.